Previous studies showed synergistic effects by combining the predecessor of revumenib, SNDX-50469 (VTP50469), with a DOT1L inhibitor in both KMT2A-rearranged and NPM1-mutated acute leukemia [35,40]. Here, KMT2A is linked to acute leukemia.